RHOA and classic Hodgkin lymphoma: In line with the ability of the RhoA-ROCK pathway to regulate cytoskeletal dynamics, the migration of several B cell malignancies, including classic Hodgkin lymphoma (cHL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM), was shown to depend on ROCK signalingin vitro15,30,31,58, and homing of MM cells to the bone marrow in xenograft models could be prevented by pre-treatment of cells with a ROCK inhibitor15.